Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

#Cybin reports #breakthrough Phase 2 data for #CYB003 in Major Depressive Disorder (#MDD), with 100% of patients responsive to treatment and 71% in remission at 12 months after just two 16mg doses. Learn more: #Neuropsychiatry #MentalHealth #Depression

Helus_Pharma's profile picture

Helus Pharma

9,287 subscribers

11,709 görüntüleme • 1 yıl önce •via X (Twitter)

Sağlık & İyilik#Cybin#breakthrough#CYB003#MDD#Neuropsychiatry#MentalHealth#Depression
LIVE

Anya Rossi• Live Now

Private livecam show

9 Yorum

Psych Investor profil fotoğrafı
Psych Investor1 yıl önce

👏👏

SportsFanatic profil fotoğrafı
SportsFanatic1 yıl önce

Incredible!! Congrats to you and the entire team!!!! 👏🏼👏🏼👏🏼

Dream State Awake profil fotoğrafı
Dream State Awake1 yıl önce

Big pharma won't like this.

Minimoose profil fotoğrafı
Minimoose1 yıl önce

Nice! Keep on Moosin' on

Altered Updates profil fotoğrafı
Altered Updates1 yıl önce

👏

Aurora profil fotoğrafı
Aurora1 yıl önce

Disappointing to see Cybin partnering with Paul Joseph Watson, who famously said "depression is nothing more than dissatisfaction with life, it's temporary unhappiness." .

B.Smith profil fotoğrafı
B.Smith1 yıl önce

👌

A Rocket profil fotoğrafı
A Rocket1 yıl önce

Not so much of a breakthrough when all companies report the same data. No competitive differentiation is possible and all psychedelics substitute for one another. Zero alpha. Returns trend to the mean. Next.

eli.bda profil fotoğrafı
eli.bda1 yıl önce

Let cybin coooooook

Benzer Videolar

We are now enrolling patients as young as 3 in our OCU410ST Phase 2/3 GARDian3 clinical trial for #Stargardtdisease. Phase 1 data shows 100% stabilization or improvement in treated eyes and 48.2% slower lesion growth. Learn more: clinical.request@ocugen.com #OCU410ST #Ocugen
1:02

We are now enrolling patients as young as 3 in our OCU410ST Phase 2/3 GARDian3 clinical trial for #Stargardtdisease. Phase 1 data shows 100% stabilization or improvement in treated eyes and 48.2% slower lesion growth. Learn more: [email protected] #OCU410ST #Ocugen

Ocugen

13,649 görüntüleme • 8 ay önce

More hospitals in England are expected to declare critical incidents as increasing numbers of patients suffering flu and other winter illnesses overwhelm A&E hospitals. Patients at 11 major hospitals are facing a wait of up to 50 hours for treatment. Jonathan Swain reports.
2:32

More hospitals in England are expected to declare critical incidents as increasing numbers of patients suffering flu and other winter illnesses overwhelm A&E hospitals. Patients at 11 major hospitals are facing a wait of up to 50 hours for treatment. Jonathan Swain reports.

Good Morning Britain

24,165 görüntüleme • 1 yıl önce

Intense infrared sauna treatment shows impressive antidepressant effects Patients with major depressive disorder undergoing intense infrared sauna sessions (raising core body temp ~2 °F) improved their depression scores by an extraordinary 16 points on the Hamilton scale (far exceeding the 3-point threshold for clinical significance) Previous research has also shown that just one infrared heat session had antidepressant benefits lasting as long as 6 weeks
3:15

Intense infrared sauna treatment shows impressive antidepressant effects Patients with major depressive disorder undergoing intense infrared sauna sessions (raising core body temp ~2 °F) improved their depression scores by an extraordinary 16 points on the Hamilton scale (far exceeding the 3-point threshold for clinical significance) Previous research has also shown that just one infrared heat session had antidepressant benefits lasting as long as 6 weeks

FoundMyFitness Clips

47,734 görüntüleme • 8 ay önce

Today we announced the initiation of a pivotal Phase 2b/3 trial for the treatment of patients with neovascular age-related macular degeneration (#wetAMD). Learn more: #ophthalmology
0:22

Today we announced the initiation of a pivotal Phase 2b/3 trial for the treatment of patients with neovascular age-related macular degeneration (#wetAMD). Learn more: #ophthalmology

Merck

16,948 görüntüleme • 3 ay önce

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Cercek explained that it essentially unlocks the body’s ability to heal itself.
3:28

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Cercek explained that it essentially unlocks the body’s ability to heal itself.

The Vigilant Fox 🦊

1,600,238 görüntüleme • 2 yıl önce

96% of patients declared COMPLETE REMISSION of alpha-gal syndrome after ear acupuncture — lasting months to years. Basically EVERYONE in the study could eat meat again within weeks of undergoing Soliman Auricular Allergy Treatment (SAAT). There were ZERO adverse reactions.
1:22

96% of patients declared COMPLETE REMISSION of alpha-gal syndrome after ear acupuncture — lasting months to years. Basically EVERYONE in the study could eat meat again within weeks of undergoing Soliman Auricular Allergy Treatment (SAAT). There were ZERO adverse reactions.

Nicolas Hulscher, MPH

837,834 görüntüleme • 1 ay önce

100% Cancer Remission Achieved in ALL Patients of Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself.
3:28

100% Cancer Remission Achieved in ALL Patients of Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself.

The Vigilant Fox 🦊

2,527,485 görüntüleme • 2 yıl önce

Psychiatrists aren't curing mental illness. They're managing it. And the stats prove it. - 1 in 5 adults in the US has a mental illness. Treatment rates are up, but so are the numbers. Where are the cures? - Antidepressant use has skyrocketed over 400% in the last two decades. If they were curative, wouldn't we see a corresponding drop in prevalence? Instead, we see long-term dependency. - Remission rates tell the real story: • Only about 1/3 of patients with Major Depressive Disorder achieve remission with their first antidepressant. • After 4 different medication attempts, the remission rate is still dismally low. This isn't to blame dedicated doctors. It's to question a system that's become about lifelong medication management rather than root-cause resolution. We're treating the symptoms, not the disease. We need a paradigm shift. More focus on therapy, lifestyle, community, and trauma-informed care. The goal must be healing, not just maintenance.
1:02

Psychiatrists aren't curing mental illness. They're managing it. And the stats prove it. - 1 in 5 adults in the US has a mental illness. Treatment rates are up, but so are the numbers. Where are the cures? - Antidepressant use has skyrocketed over 400% in the last two decades. If they were curative, wouldn't we see a corresponding drop in prevalence? Instead, we see long-term dependency. - Remission rates tell the real story: • Only about 1/3 of patients with Major Depressive Disorder achieve remission with their first antidepressant. • After 4 different medication attempts, the remission rate is still dismally low. This isn't to blame dedicated doctors. It's to question a system that's become about lifelong medication management rather than root-cause resolution. We're treating the symptoms, not the disease. We need a paradigm shift. More focus on therapy, lifestyle, community, and trauma-informed care. The goal must be healing, not just maintenance.

Camus

19,737 görüntüleme • 8 ay önce

Today, we announced the completion of enrollment in our global BROADEN2 Phase 2b trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in atopic dermatitis, nearly six months ahead of anticipated timelines. This milestone enables us to accelerate our expected topline data readout to year-end 2026 and continue advancing KT-621 as a potential oral treatment option for patients living with atopic dermatitis and other Type 2 inflammatory diseases. Read more in our press release:
0:45

Today, we announced the completion of enrollment in our global BROADEN2 Phase 2b trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in atopic dermatitis, nearly six months ahead of anticipated timelines. This milestone enables us to accelerate our expected topline data readout to year-end 2026 and continue advancing KT-621 as a potential oral treatment option for patients living with atopic dermatitis and other Type 2 inflammatory diseases. Read more in our press release:

Kymera Therapeutics

19,878 görüntüleme • 18 gün önce

Nattokinase is truly a remarkable supplement. At 10,800 FU daily, it reverses arterial plague in 66.5% of patients over 12 months, with no side effects. The rest of the data is even more insane:
1:07

Nattokinase is truly a remarkable supplement. At 10,800 FU daily, it reverses arterial plague in 66.5% of patients over 12 months, with no side effects. The rest of the data is even more insane:

Dr. Biohacker

88,674 görüntüleme • 23 gün önce

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself. Watch the breakdown of this study in the comment below.
2:18

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself. Watch the breakdown of this study in the comment below.

The Vigilant Fox 🦊

1,690,044 görüntüleme • 2 yıl önce

A recent study found 96% of alpha-gal syndrome patients could EAT MEAT AGAIN within weeks of specialized ear acupuncture. Nearly EVERYONE in the study declared COMPLETE REMISSION of alpha-gal syndrome after Soliman Auricular Allergy Treatment (SAAT), lasting months to years.
1:23

A recent study found 96% of alpha-gal syndrome patients could EAT MEAT AGAIN within weeks of specialized ear acupuncture. Nearly EVERYONE in the study declared COMPLETE REMISSION of alpha-gal syndrome after Soliman Auricular Allergy Treatment (SAAT), lasting months to years.

Nicolas Hulscher, MPH

120,804 görüntüleme • 1 ay önce

Palestinians in Khan Younis in southern Gaza celebrated and chanted together on Thursday after U.S. President Donald Trump announced that the parties had agreed to the “first phase” of a deal signaling a major breakthrough in the two-year war in Gaza.
0:37

Palestinians in Khan Younis in southern Gaza celebrated and chanted together on Thursday after U.S. President Donald Trump announced that the parties had agreed to the “first phase” of a deal signaling a major breakthrough in the two-year war in Gaza.

The Associated Press

64,920 görüntüleme • 9 ay önce

B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. Full results and Research Summary:
1:32

B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. Full results and Research Summary:

NEJM

15,827 görüntüleme • 15 gün önce

Animal-based ketogenic diet leads to remission of anxiety and depression in clinical study
1:02

Animal-based ketogenic diet leads to remission of anxiety and depression in clinical study

Dr Shawn Baker 🥩

31,550 görüntüleme • 1 yıl önce

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹The interim Phase 1 clinical data for REC-617 included: ▫️Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▫️Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▫️In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." 👉Learn more: 🔹Join the Update Call: Tomorrow, Tues., Dec. 10 at 8:30am ET, Dr. Hallett and Dr. Khan will hold a live Update Call webcast to present the preliminary data. ▫️Submit questions for the Update Call here: ▫️Tune in to the Update Call here on X or on: LinkedIn: YouTube:
0:20

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹The interim Phase 1 clinical data for REC-617 included: ▫️Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▫️Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▫️In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." 👉Learn more: 🔹Join the Update Call: Tomorrow, Tues., Dec. 10 at 8:30am ET, Dr. Hallett and Dr. Khan will hold a live Update Call webcast to present the preliminary data. ▫️Submit questions for the Update Call here: ▫️Tune in to the Update Call here on X or on: LinkedIn: YouTube:

Recursion

11,879 görüntüleme • 1 yıl önce

Six Men Arrested and Two Injured Following Serious Disorder Detectives in #Halifax are investigating after reports of violent disorder on Mile Cross Road in the town yesterday afternoon. Officers responded to reports of fighting and that weapons and vehicles were involved in the incident. Two men were seriously injured as a result of the disorder. Both remain in hospital where their injuries are not believed to be life threatening. Six men have been arrested in connection with the incident as enquiries continue.
1:28

Six Men Arrested and Two Injured Following Serious Disorder Detectives in #Halifax are investigating after reports of violent disorder on Mile Cross Road in the town yesterday afternoon. Officers responded to reports of fighting and that weapons and vehicles were involved in the incident. Two men were seriously injured as a result of the disorder. Both remain in hospital where their injuries are not believed to be life threatening. Six men have been arrested in connection with the incident as enquiries continue.

Yapp

15,996 görüntüleme • 1 yıl önce

New Research: Ketogenic Diet Associated with Improvements in Depression in College Students The first ever peer-reviewed pilot trial of ketogenic diet for depression was published today in Translational Psychiatry. The study was conducted in college students with a primary diagnosis of major depressive disorder at The Ohio State University. All 16 students who completed the study saw improvements in depression, with an average reduction in symptoms of 70% across scales. Metabolic health markers also improved. The video below includes perspectives from the research team and students who participated in the study. Read the full study in Translational Psychiatry: Read Ohio State News announcement:
5:05

New Research: Ketogenic Diet Associated with Improvements in Depression in College Students The first ever peer-reviewed pilot trial of ketogenic diet for depression was published today in Translational Psychiatry. The study was conducted in college students with a primary diagnosis of major depressive disorder at The Ohio State University. All 16 students who completed the study saw improvements in depression, with an average reduction in symptoms of 70% across scales. Metabolic health markers also improved. The video below includes perspectives from the research team and students who participated in the study. Read the full study in Translational Psychiatry: Read Ohio State News announcement:

Metabolic Mind

82,360 görüntüleme • 10 ay önce